Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

DOI record: { "DOI": "10.1038/s41598-021-89444-5", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-021-89444-5", "abstract": "<jats:title>Abstract</jats:title><jats:p>Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe COVID-19. Twenty COVID-19 patients received two 200 ml transfusions of convalescent patient CP over 24-h compared with 20 who received standard of care. The primary outcome was the requirement for ventilation (non-invasive or mechanical ventilation). The secondary outcomes were biochemical parameters and mortality at 28 days. The CP group were a higher risk group with higher ferritin levels (<jats:italic>p</jats:italic> &lt; 0.05) though respiratory indices did not differ. The primary outcome measure was required in 6 controls and 4 patients on CP (risk ratio 0.67, 95% CI 0.22–2.0, <jats:italic>p</jats:italic> = 0.72); mean time on ventilation (NIV or MV) did not differ. There were no differences in secondary measures at the end of the study. Two patients died in the control and one patient in the CP arm. There were no significant differences in the primary or secondary outcome measures between CP and standard therapy, although a larger definitive study is needed for confirmation. However, the study did show that CP therapy appears to be safe in hospitalized COVID-19 patients with hypoxia.</jats:p><jats:p><jats:italic>Clinical trials registration</jats:italic> NCT04356534: 22/04/2020.</jats:p>", "alternative-id": [ "89444" ], "article-number": "9927", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "11 December 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "23 April 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "11 May 2021" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "AlQahtani", "given": "Manaf", "sequence": "first" }, { "affiliation": [], "family": "Abdulrahman", "given": "Abdulkarim", "sequence": "additional" }, { "affiliation": [], "family": "Almadani", "given": "Abdulrahman", "sequence": "additional" }, { "affiliation": [], "family": "Alali", "given": "Salman Yousif", "sequence": "additional" }, { "affiliation": [], "family": "Al Zamrooni", "given": "Alaa Mahmood", "sequence": "additional" }, { "affiliation": [], "family": "Hejab", "given": "Amal Hamza", "sequence": "additional" }, { "affiliation": [], "family": "Conroy", "given": "Ronán M.", "sequence": "additional" }, { "affiliation": [], "family": "Wasif", "given": "Pearl", "sequence": "additional" }, { "affiliation": [], "family": "Otoom", "given": "Sameer", "sequence": "additional" }, { "affiliation": [], "family": "Atkin", "given": "Stephen L.", "sequence": "additional" }, { "affiliation": [], "family": "Abduljalil", "given": "Manal", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 5, 11 ] ], "date-time": "2021-05-11T10:09:20Z", "timestamp": 1620727760000 }, "deposited": { "date-parts": [ [ 2022, 12, 3 ] ], "date-time": "2022-12-03T08:01:55Z", "timestamp": 1670054515000 }, "indexed": { "date-parts": [ [ 2024, 3, 29 ] ], "date-time": "2024-03-29T06:39:12Z", "timestamp": 1711694352867 }, "is-referenced-by-count": 71, "issue": "1", "issued": { "date-parts": [ [ 2021, 5, 11 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 11 ] ], "date-time": "2021-05-11T00:00:00Z", "timestamp": 1620691200000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 11 ] ], "date-time": "2021-05-11T00:00:00Z", "timestamp": 1620691200000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-021-89444-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-021-89444-5", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-021-89444-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2021, 5, 11 ] ] }, "published-online": { "date-parts": [ [ 2021, 5, 11 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "89444_CR1", "unstructured": "Coronavirus Update (Live): 46,432,714 Cases and 1,200,927 Deaths from COVID-19 Virus Pandemic - Worldometer. Worldometers.info. https://www.worldometers.info/coronavirus/." }, { "DOI": "10.1056/NEJMoa2007764", "author": "JH Beigel", "doi-asserted-by": "publisher", "journal-title": "N. Engl. J. Med.", "key": "89444_CR2", "unstructured": "Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—Preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).", "year": "2020" }, { "DOI": "10.1002/jmv.26047", "author": "KK Sahu", "doi-asserted-by": "publisher", "first-page": "2251", "issue": "11", "journal-title": "J. Med. Virol.", "key": "89444_CR3", "unstructured": "Sahu, K. K., Jindal, V., Siddiqui, A. D., Cerny, J. & Gerber, J. M. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19. J. Med. Virol. 92(11), 2251–2253. https://doi.org/10.1002/jmv.26047 (2020).", "volume": "92", "year": "2020" }, { "DOI": "10.1111/j.1469-0691.2004.00956.x", "author": "YO Soo", "doi-asserted-by": "publisher", "first-page": "676", "issue": "7", "journal-title": "Clin. Microbiol. Infect.", "key": "89444_CR4", "unstructured": "Soo, Y. O. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 10(7), 676–678. https://doi.org/10.1111/j.1469-0691.2004.00956.x (2004).", "volume": "10", "year": "2004" }, { "DOI": "10.1016/j.jinf.2016.11.009", "author": "F Sahr", "doi-asserted-by": "publisher", "first-page": "302", "issue": "3", "journal-title": "J. Infect.", "key": "89444_CR5", "unstructured": "Sahr, F. et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J. Infect. 74(3), 302–309. https://doi.org/10.1016/j.jinf.2016.11.009 (2017).", "volume": "74", "year": "2017" }, { "DOI": "10.1093/cid/ciq106", "author": "IF Hung", "doi-asserted-by": "publisher", "first-page": "447", "issue": "4", "journal-title": "Clin. Infect. Dis.", "key": "89444_CR6", "unstructured": "Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52(4), 447–456. https://doi.org/10.1093/cid/ciq106 (2011).", "volume": "52", "year": "2011" }, { "DOI": "10.1001/jama.2020.4783", "author": "C Shen", "doi-asserted-by": "publisher", "journal-title": "JAMA", "key": "89444_CR7", "unstructured": "Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA https://doi.org/10.1001/jama.2020.4783 (2020).", "year": "2020" }, { "DOI": "10.1001/jama.2020.10044", "author": "L Li", "doi-asserted-by": "publisher", "first-page": "1", "issue": "5", "journal-title": "JAMA", "key": "89444_CR8", "unstructured": "Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA 324(5), 1–11. https://doi.org/10.1001/jama.2020.10044 (2020).", "volume": "324", "year": "2020" }, { "key": "89444_CR9", "unstructured": "Gharbharan, A., et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv. 2020." }, { "DOI": "10.1101/2020.08.12.20169359", "author": "MJ Joyner", "doi-asserted-by": "publisher", "journal-title": "medRxiv", "key": "89444_CR10", "unstructured": "Joyner, M. J. et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medRxiv https://doi.org/10.1101/2020.08.12.20169359 (2020).", "year": "2020" }, { "DOI": "10.2807/1560-7917.Es.2020.25.3.2000045", "author": "VM Corman", "doi-asserted-by": "publisher", "journal-title": "Eurosurveillance", "key": "89444_CR11", "unstructured": "Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance https://doi.org/10.2807/1560-7917.Es.2020.25.3.2000045 (2020).", "year": "2020" }, { "DOI": "10.1002/sim.4780132309", "author": "MA Birkett", "doi-asserted-by": "publisher", "first-page": "2455", "issue": "23–24", "journal-title": "Stat. Med.", "key": "89444_CR12", "unstructured": "Birkett, M. A. & Day, S. J. Internal pilot studies for estimating sample size. Stat. Med. 13(23–24), 2455–2463 (1994).", "volume": "13", "year": "1994" }, { "author": "R Newson", "first-page": "497", "issue": "4", "journal-title": "Stand. Genom. Sci.", "key": "89444_CR13", "unstructured": "Newson, R. Confidence intervals for rank statistics: Percentile slopes, differences, and ratios. Stand. Genom. Sci. 6(4), 497–520 (2006).", "volume": "6", "year": "2006" }, { "DOI": "10.15585/mmwr.mm6913e2", "doi-asserted-by": "publisher", "key": "89444_CR14", "unstructured": "Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12-March 28, 2020. MMWR. 2020;69(13):382–386. https://doi.org/10.15585/mmwr.mm6913e2." }, { "DOI": "10.1016/j.ajem.2020.12.076", "author": "TI Hariyanto", "doi-asserted-by": "publisher", "first-page": "110", "journal-title": "Am. J. Emerg. Med.", "key": "89444_CR15", "unstructured": "Hariyanto, T. I. et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. Am. J. Emerg. Med. 41, 110–119. https://doi.org/10.1016/j.ajem.2020.12.076 (2020).", "volume": "41", "year": "2020" }, { "DOI": "10.1002/jcla.23618", "author": "L Cheng", "doi-asserted-by": "publisher", "first-page": "e23618", "issue": "10", "journal-title": "J. Clin. Lab. Anal.", "key": "89444_CR16", "unstructured": "Cheng, L. et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J. Clin. Lab. Anal. 34(10), e23618. https://doi.org/10.1002/jcla.23618 (2020).", "volume": "34", "year": "2020" }, { "DOI": "10.1038/d41586-020-01824-5", "author": "H Ledford", "doi-asserted-by": "publisher", "first-page": "469", "issue": "7813", "journal-title": "Nature", "key": "89444_CR17", "unstructured": "Ledford, H. Coronavirus breakthrough: Dexamethasone is first drug shown to save lives. Nature 582(7813), 469. https://doi.org/10.1038/d41586-020-01824-5 (2020).", "volume": "582", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001282", "author": "B Cao", "doi-asserted-by": "publisher", "first-page": "1787", "issue": "19", "journal-title": "N. Engl. J. Med.", "key": "89444_CR18", "unstructured": "Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382(19), 1787–1799. https://doi.org/10.1056/NEJMoa2001282 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1016/s0140-6736(20)31042-4", "author": "IF Hung", "doi-asserted-by": "publisher", "first-page": "1695", "issue": "10238", "journal-title": "Lancet", "key": "89444_CR19", "unstructured": "Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet 395(10238), 1695–1704. https://doi.org/10.1016/s0140-6736(20)31042-4 (2020).", "volume": "395", "year": "2020" }, { "DOI": "10.1056/NEJMoa2019014", "author": "AB Cavalcanti", "doi-asserted-by": "publisher", "journal-title": "N. Engl. J. Med.", "key": "89444_CR20", "unstructured": "Cavalcanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2019014 (2020).", "year": "2020" }, { "DOI": "10.1172/jci140200", "author": "MJ Joyner", "doi-asserted-by": "publisher", "journal-title": "J. Clin. Investig.", "key": "89444_CR21", "unstructured": "Joyner, M. J. et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J. Clin. Investig. https://doi.org/10.1172/jci140200 (2020).", "year": "2020" }, { "DOI": "10.1016/j.mayocp.2020.06.028", "author": "MJ Joyner", "doi-asserted-by": "publisher", "first-page": "1888", "issue": "9", "journal-title": "Mayo Clin.", "key": "89444_CR22", "unstructured": "Joyner, M. J. et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin. 95(9), 1888–1897. https://doi.org/10.1016/j.mayocp.2020.06.028 (2020).", "volume": "95", "year": "2020" }, { "DOI": "10.1186/s13054-019-2683-3", "author": "F Sanfilippo", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Crit. Care", "key": "89444_CR23", "unstructured": "Sanfilippo, F., La Rosa, V., Oliveri, F. & Astuto, M. Convalescent plasma for COVID-19: The risk of pulmonary embolism should not be underestimated!. Crit. Care 24, 1–2 (2020).", "volume": "24", "year": "2020" }, { "DOI": "10.1136/bmj.m4072", "author": "EB Pathak", "doi-asserted-by": "publisher", "first-page": "m4072", "journal-title": "BMJ", "key": "89444_CR24", "unstructured": "Pathak, E. B. Convalescent plasma is ineffective for covid-19. BMJ 371, m4072. https://doi.org/10.1136/bmj.m4072 (2020).", "volume": "371", "year": "2020" }, { "key": "89444_CR25", "unstructured": "Recommendations for Investigational COVID-19 Convalescent Plasma. Food and Drug Administration. Accessed September 2, 2020, https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma." }, { "DOI": "10.1136/bmj.m3939", "author": "A Agarwal", "doi-asserted-by": "publisher", "first-page": "m3939", "journal-title": "BMJ", "key": "89444_CR26", "unstructured": "Agarwal, A. et al. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 371, m3939. https://doi.org/10.1136/bmj.m3939 (2020).", "volume": "371", "year": "2020" }, { "DOI": "10.1101/2020.07.01.20139857", "author": "A Gharbharan", "doi-asserted-by": "publisher", "journal-title": "medRxiv", "key": "89444_CR27", "unstructured": "Gharbharan, A. et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv https://doi.org/10.1101/2020.07.01.20139857 (2020).", "year": "2020" }, { "DOI": "10.1056/NEJMoa2031304", "author": "VA Simonovich", "doi-asserted-by": "publisher", "first-page": "619", "issue": "7", "journal-title": "N. Engl. J. Med.", "key": "89444_CR28", "unstructured": "Simonovich, V. A. et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N. Engl. J. Med. 384(7), 619–629. https://doi.org/10.1056/NEJMoa2031304 (2021).", "volume": "384", "year": "2021" } ], "reference-count": 28, "references-count": 28, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.1101/2020.11.02.20224303", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-021-89444-5" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "11" }